Skip to main content

News

All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The newly developed analytical workflow could in the future be introduced as a comprehensive diagnostic test for patients with mitochondrial diseases.